Aimed at those who are eager to hear about and discuss some of the latest developments in Cancer Immno oncology (IO), our distinguished panel will focus the forum discussion on dose-finding, biomarker development and endpoints for IO and IO-IO combination clinical trials. For those not familiar with IO we’ll provide a brief including basic principles and a few examples like checkpoint inhibitors. We’ll explore what is different for IO and for IO-IO combinations dose finding compared with traditional chemo dose finding. You’ll learn about new strategies underway for IO biomarker development that can help speed up development such as seamless adaptive designs, introduction of Bayesian paradigm into frequentist designs, and more. Finally, we will wrap up with a look at modern techniques for clinical trial endpoints and statistics including PFS versus OS as primary and RECIST vs irRECIST. Come join this interactive conversation.